CL2020000360A1 - Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica. - Google Patents
Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica.Info
- Publication number
- CL2020000360A1 CL2020000360A1 CL2020000360A CL2020000360A CL2020000360A1 CL 2020000360 A1 CL2020000360 A1 CL 2020000360A1 CL 2020000360 A CL2020000360 A CL 2020000360A CL 2020000360 A CL2020000360 A CL 2020000360A CL 2020000360 A1 CL2020000360 A1 CL 2020000360A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- treatment
- compounds
- compositions
- indazole compounds
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 3
- 239000003623 enhancer Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009251 neurologic dysfunction Effects 0.000 title 1
- 208000015015 neurological dysfunction Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000360A1 true CL2020000360A1 (es) | 2020-07-31 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000360A CL2020000360A1 (es) | 2017-08-16 | 2020-02-12 | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US11427573B2 (https=) |
| EP (1) | EP3668865A1 (https=) |
| JP (1) | JP7253832B2 (https=) |
| KR (1) | KR102687118B1 (https=) |
| CN (1) | CN111225913B (https=) |
| AU (1) | AU2018317403B2 (https=) |
| BR (1) | BR112020003292A2 (https=) |
| CA (1) | CA3072493A1 (https=) |
| CL (1) | CL2020000360A1 (https=) |
| CO (1) | CO2020002576A2 (https=) |
| EA (1) | EA202090467A1 (https=) |
| IL (1) | IL272575B2 (https=) |
| PE (1) | PE20200756A1 (https=) |
| SG (1) | SG11202001264UA (https=) |
| UA (1) | UA128084C2 (https=) |
| WO (1) | WO2019036534A1 (https=) |
| ZA (1) | ZA202001321B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11242342B2 (en) | 2016-11-08 | 2022-02-08 | Vanderbilt University | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| IL272575B2 (en) | 2017-08-16 | 2023-09-01 | Univ Vanderbilt | Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction |
| WO2021007477A1 (en) | 2019-07-11 | 2021-01-14 | E-Scape Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| JP2025540259A (ja) * | 2022-12-08 | 2025-12-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換ピラジン－カルボキサミド－イミダゾピリジン誘導体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668811A1 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| EP2120932B1 (en) | 2006-12-20 | 2014-07-09 | Nerviano Medical Sciences S.r.l. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| SG173465A1 (en) | 2009-01-28 | 2011-09-29 | Univ Vanderbilt | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| JP2013500267A (ja) | 2009-07-23 | 2013-01-07 | ヴァンダービルト ユニバーシティー | ｍＧＬｕＲ４増強剤としての置換されたベンゾイミダゾールスルホンアミド類および置換されたインドールスルホンアミド類 |
| RU2012114770A (ru) | 2009-09-04 | 2013-10-10 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| BR112012009576A2 (pt) | 2009-10-22 | 2019-09-24 | Univ Vanderbilt | potencializador alostérico de mglur4, composições, e métodos de tratamento de disfunção neurológica |
| BR112012010738A2 (pt) | 2009-11-06 | 2019-09-24 | Univ Vanderbilt | ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica'' |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| BR112012020273A8 (pt) | 2010-02-11 | 2017-12-26 | Univ Vanderbilt | compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica |
| WO2011100614A1 (en) | 2010-02-11 | 2011-08-18 | Vanderbilt University | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION |
| BR112012028894A2 (pt) | 2010-05-12 | 2019-09-24 | Univ Vanderbilt | sulfona heterocíclica como potenciadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| MX2016012208A (es) | 2014-03-20 | 2017-01-26 | Samumed Llc | Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas. |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| US9980945B2 (en) | 2015-01-13 | 2018-05-29 | Vanderbilt University | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11242342B2 (en) | 2016-11-08 | 2022-02-08 | Vanderbilt University | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| IL272575B2 (en) | 2017-08-16 | 2023-09-01 | Univ Vanderbilt | Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction |
-
2018
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 KR KR1020207007596A patent/KR102687118B1/ko active Active
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt active IP Right Grant
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en not_active Ceased
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US12291521B2/en active Active
-
2025
- 2025-05-06 US US19/200,356 patent/US20260070897A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260070897A1 (en) | 2026-03-12 |
| AU2018317403B2 (en) | 2023-09-21 |
| KR20200054204A (ko) | 2020-05-19 |
| PE20200756A1 (es) | 2020-07-27 |
| US10508105B2 (en) | 2019-12-17 |
| EP3668865A1 (en) | 2020-06-24 |
| JP7253832B2 (ja) | 2023-04-07 |
| US20200291019A1 (en) | 2020-09-17 |
| CN111225913B (zh) | 2024-05-31 |
| EA202090467A1 (ru) | 2020-06-18 |
| CO2020002576A2 (es) | 2020-04-01 |
| IL272575B1 (en) | 2023-05-01 |
| ZA202001321B (en) | 2023-10-25 |
| CN111225913A (zh) | 2020-06-02 |
| WO2019036534A1 (en) | 2019-02-21 |
| SG11202001264UA (en) | 2020-03-30 |
| JP2020531454A (ja) | 2020-11-05 |
| US11427573B2 (en) | 2022-08-30 |
| IL272575B2 (en) | 2023-09-01 |
| CA3072493A1 (en) | 2019-02-21 |
| BR112020003292A2 (pt) | 2020-08-18 |
| UA128084C2 (uk) | 2024-04-03 |
| US12291521B2 (en) | 2025-05-06 |
| AU2018317403A1 (en) | 2020-03-12 |
| IL272575A (en) | 2020-03-31 |
| KR102687118B1 (ko) | 2024-07-19 |
| US20190055225A1 (en) | 2019-02-21 |
| US20220259190A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000360A1 (es) | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica. | |
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CL2019000827A1 (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador. | |
| MX2019006637A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador. | |
| GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| MX2018009952A (es) | Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1. | |
| SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| CL2019001129A1 (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y. | |
| MX2020013085A (es) | Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos. | |
| BR112012020273A2 (pt) | Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| CL2008002744A1 (es) | Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2. | |
| MX2018014202A (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| BR112012020271A2 (pt) | Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica | |
| MX2020003185A (es) | Nuevos compuestos heterociclicos. | |
| NZ739139A (en) | Dopamine d3 receptor antagonists having a bicyclo moiety | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| BR112018005589A2 (pt) | “composto, composição farmaceuticamente aceitável, e, uso de um composto” | |
| BR112018016629A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 | |
| MX2020000693A (es) | Compuestos de 1,8-naftiridinona, y usos de los mismos. |